All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld MedTech Perspectives » Risks and patients: Should FDA and industry close the perception gap?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / CDRH / FDA

Risks and patients: Should FDA and industry close the perception gap?

Dec. 1, 2011
By Mark McCarty
No Comments

When patients can see you, but can't hear you

As mentioned in a posting earlier this week, my wife and I were out for dinner recently and made the acquaintance of some opinions about FDA and the industries it regulates. Opinions about FDA ranged from awful to terrible, and doctors and industry fared no better. It seems a lot of people think user fees conscript FDA, and some see the agency, industry and physicians as some sort of malevolent troika that would have made the Kremlin of Leonid Brezhnev proud.

Maybe I'm too close to it all to appreciate the nefariousness, but I wonder how anyone comes to see things that way, not to mention how many see it that way. Here's the question, though: If those perceptions are widespread, why are such things allowed to fester? One can easily understand why FDA and device makers might dismiss this kind of prattle from a member of the trade press, but it's not just me who thinks this ought not go unaddressed.

I recently interviewed Bray Patrick-Lake, President/CEO of the PFO Research Foundation (Boulder, Colorado), who appeared at Transcatheter Cardiovascular Therapeutics. One of her remarks at TCT 2011 was some patients “actually believe that when [a drug or device] is FDA approved, the risks are zero.” As covered in the Nov. 30 edition of Medical Device Daily, Patrick-Lake also told the audience at TCT, “if we don't do a better job of educating patients … we will continue to see lawsuits and backlash” against agency and industry alike.

During our interview, Patrick-Lake said that some patients are “asleep at the wheel” where the risks and benefits of a drug, device or procedure are concerned. She indicated that a failure to appreciate the risks can leave a patient with one of those unintended consequences that seems a bad trade-off, even if their life was saved in the process. A better appreciation for those risks might change a few minds about which treatment to select, Patrick-Lake suggested, but at the very least would avoid the kind of psychological whiplash that goes along with finding out the ride wasn't free of risk after all.

All the same, Patrick-Lake was not inclined to let FDA, docs and industry off the hook. “What gets advertised or what ends up on 20-20 … is never what happens to the average patient,” she said of DTC ads and sensationalistic media coverage, making the argument that the gap between the two is where device makers and FDA need to put forth some effort.

Patrick-Lake acknowledged that all the data on patient sub-populations means that a lot of work will go into the production of disease-specific patient education material (not to mention updating that material as new data emerge), but she also said that a more general public information campaign might work wonders for those who are not yet patients, giving them the heads-up on what to look for once they end up under a doctor's care.

Patrick-Lake said a public service campaign intended to make the audience aware of risks “would be very simple to do, and I don't think it would be that expensive.” She also remarked, “I can't imagine industry would have anything to lose over patients being better informed,” stating that both industry and FDA bear some responsibility to do something along these lines.

“It can be done and it should be done,” she said.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing